Veuillez noter que cette partie du site n’est disponible qu’en Anglais

ISTILOS™ B. infantis

ISTILOS B. infantis* is believed to support gut barrier function and the development of the immune system in infants

About ISTILOS B. infantis

  • The probiotic strain ISTILOS B. infantis was isolated from the intestine of a healthy infant. 
  • It is safe for consumption, the species has a QPS (Qualified Presumption of Safety) status in Europe. The ISTILOS B. infantis strain has been notified as GRAS (Generally Recognized as Safe), with "no questions" from the U.S. Food and Drug Administration (FDA) in March 2021 (GRN no. 950).
  • It has been used since the early 2000s as an ingredient in food and food supplements. 
  • The benefits of this strain have been known for decades, supported by high-quality clinical studies.
  • In 2023, Bifidobacterium longum subsp. infantis, Bifin02™* was trademarked with the commercial name ISTILOS B. infantis

Clinically demonstrated health benefits 

As part of a three-strain blend investigated in clinical trials and pre-clinical studies, ISTILOS B. infantis was shown to:

  • Seed and thrive in the infant gut1
  • Produce metabolites that are known to be involved in the development of the immune system and support gut barrier function1,2

Clinical studies involving ISTILOS B. infantis

The probiotic strain ISTILOS has been demonstrated to effectively colonize the infant gut in a recent clinical trial and produce metabolites known to help develop the immune system and support gut barrier function.1, 2

In an open-label trial1, 23 newborns received a three-strain blend containing ISTILOS B. infantis, Bifidobacterium animalis subsp. lactis, BB-12®, and L. rhamnosus LGG® for 28 days. The ISTILOS strain was detected in the stool of all the newborns in increasing quantities even after supplementation ceased, demonstrating that the probiotic strain ISTILOS could seed and thrive in the gut of these infants.


Strict production requirements ensure the highest quality

In general, when delivering products intended for infant use Chr. Hansen has implemented the strictest of production processes. Chr. Hansen’s extra requirements include extended contaminant testing and stricter requirements regarding both environmental monitoring and cleaning before production to eliminate the risk of contamination.


ISTILOS, BB-12® and TH-4® are registered trademarks of Chr. Hansen A/S  


* Naming history

The probiotic strain ISTILOS B. infantis has been or is known by the following names:

  • Bifidobacterium longum subsp. infantis, Bifin02 (DSM33361)
  • Bifidobacterium infantis, BB-02 (DSM 33361)


1 Melsaether C, et al. Nutrients. 2023;15(18): 4000.
2 Internal Chr. Hansen data, 2023 (soon to be published)

Le présent communiqué s’adresse uniquement aux entreprises et aux professionnels de la santé. Ce communiqué n’est pas destiné aux consommateurs de produits de consommation finale. Aucune mention dans cette page ne doit être interprétée comme une allégation approuvée.